Search results
Pfizer Failure in Duchenne Muscular Dystrophy Trial Leaves Field Open for a Rival
Barrons.com· 3 hours agoPfizer disclosed on May 7 that a child participating in another...
Pfizer Lingers Near 11-Year Low Despite Promising Cancer Drug Updates — Is It A Sell?
Investor's Business Daily· 1 day agoDespite a bevy of promising updates for its cancer treatments, Pfizer stock remains trapped below a...
Pfizer (PFE) Phase III DMD Gene Therapy Study Misses Goal
Zacks via Yahoo Finance· 7 hours agoPfizer's (PFE) phase III study, CIFFREO, fails to show improvement in motor function in ambulatory...
Pfizer, Flagship to focus on obesity drugs under $100M collaboration - Boston Business Journal
The Business Journals· 1 day agoAlmost a year after Cambridge’s Flagship Pioneering and Pfizer Inc. announced a partnership to...
Pfizer’s gene-therapy trial failure boosts Sarepta’s stock
Market Watch· 7 hours agogained 4% premarket on Thursday after a potential competitor to its gene therapy stumbled in a...
Sarepta Jumps After Pfizer's Rival Gene Therapy Flops In Phase 3 Test
Investor's Business Daily· 6 hours agoSarepta stock jumped Thursday after Pfizer's rival gene therapy for Duchenne muscular dystrophy...
Pfizer setback brings questions for Duchenne gene therapy ahead of Sarepta decision
BioPharma Dive via Yahoo Finance· 9 hours agoThe failure of another trial adds to uncertainty around the benefits of the gene-based treatments,...
Sarepta Therapeutics gains as Pfizer failure removes overhang By Investing.com
Investing.com· 5 hours agoSarepta Therapeutics (NASDAQ:SRPT) stock rose over 3% Thursday after Pfizer (NYSE:PFE) announced...
Pfizer’s Phase III DMD gene therapy trial misses primary endpoint
Clinical Trials Arena via Yahoo Finance· 12 hours agoPfizer has reported that its Phase III CIFFREO clinical trial of investigational mini-dystrophin...
Bridgeway Capital Management LLC Boosts Stock Position in Pfizer Inc. (NYSE:PFE)
ETF DAILY NEWS· 9 hours agoBridgeway Capital Management LLC boosted its holdings in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 26.0% during the 4th quarter, according to its most recent 13F filing ...